Assessment of IL-1β, IL-6, TNF-α, IL-8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis.
CCL5
IL-1β
IL-6
IL-8
TNF-α
rheumatoid arthritis (RA)
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
03
06
2022
received:
24
03
2022
accepted:
11
06
2022
pubmed:
25
6
2022
medline:
8
9
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder which mainly affects small joints, occurs most commonly in middle-aged adults, and can be fatal in severe cases. The exact etiology of RA remains unknown. However, uncontrolled expression of pro-inflammatory cytokines and chemokines can contribute to the pathogenesis of RA. In the current study, we assessed the potential of serum concentrations of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, IL-8, and C-C motif chemokine ligand (CCL)5 as early predictive markers for RA. In addition to clinical examination, blood samples were collected from 100 Saudi patients recently diagnosed with early RA for basic and serological tests, including rheumatoid factor (RF), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Sera of 32 healthy individuals were used as controls. Specific enzyme-linked immunosorbent assay was used to quantify the serum IL-1β, IL-6, TNF-α, IL-8, and CCL5 levels in the samples. Our results indicated that RF, CRP, and ESR levels were higher in RA patients compared to controls. Furthermore, serum levels of IL-1β, IL-6, IL-8, and CCL5, but not TNF-α, significantly increased in RA patients compared to controls. Overall, the findings suggested that IL-1β, IL-6, IL-8, and CCL5 can be used as biomarkers in the early diagnosis of RA.
Sections du résumé
BACKGROUND
BACKGROUND
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder which mainly affects small joints, occurs most commonly in middle-aged adults, and can be fatal in severe cases. The exact etiology of RA remains unknown. However, uncontrolled expression of pro-inflammatory cytokines and chemokines can contribute to the pathogenesis of RA.
AIM
OBJECTIVE
In the current study, we assessed the potential of serum concentrations of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, IL-8, and C-C motif chemokine ligand (CCL)5 as early predictive markers for RA.
METHODS
METHODS
In addition to clinical examination, blood samples were collected from 100 Saudi patients recently diagnosed with early RA for basic and serological tests, including rheumatoid factor (RF), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Sera of 32 healthy individuals were used as controls. Specific enzyme-linked immunosorbent assay was used to quantify the serum IL-1β, IL-6, TNF-α, IL-8, and CCL5 levels in the samples.
RESULTS
RESULTS
Our results indicated that RF, CRP, and ESR levels were higher in RA patients compared to controls. Furthermore, serum levels of IL-1β, IL-6, IL-8, and CCL5, but not TNF-α, significantly increased in RA patients compared to controls.
CONCLUSION
CONCLUSIONS
Overall, the findings suggested that IL-1β, IL-6, IL-8, and CCL5 can be used as biomarkers in the early diagnosis of RA.
Identifiants
pubmed: 35748059
doi: 10.1111/1756-185X.14373
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
Interleukin-8
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Rheumatoid Factor
9009-79-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1013-1019Subventions
Organisme : Deanship of Scientific Research at Majmaah University
ID : R-2022-195
Informations de copyright
© 2022 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol. 2008;22(4):583-604.
Lubberts E, van den Berg WB. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv Exp Med Biol. 2003;520:194-202.
Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277-1289.
Sharma UR, Nediyedath Rathnakaran A, Raj BPP, et al. The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy. Inflammopharmacology. 2021;29(4):987-1000.
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One. 2014;9(5):e95346.
Mjaavatten MD, Bykerk VP. Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA. Best Pract Res Clin Rheumatol. 2013;27(4):451-466.
Padyukov L, Lampa J, Heimburger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003;62(6):526-529.
Almoallim HM, Alharbi LA. Rheumatoid arthritis in Saudi Arabia. Saudi Med J. 2014;35(12):1442-1454.
Sanmarti R, Ruiz-Esquide V, Hernandez MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr Top Med Chem. 2013;13(6):698-704.
Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;2(3):236-243.
Dissanayake K, Jayasinghe C, Wanigasekara P, Sominanda A. Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-alpha, IL-1beta, IL-10 and IL-17A. PLoS One. 2021;16(1):e0246111.
Littlejohn EA, Monrad SU. Early diagnosis and treatment of Rheumatoid arthritis. Prim Care. 2018;45(2):237-255.
Wasserman A. Rheumatoid arthritis: common questions about diagnosis and management. Am Fam Physician. 2018;97(7):455-462.
Zhao JX, Li ZG. The challenges of early diagnosis and therapeutic prediction in rheumatoid arthritis. Int J Rheum Dis. 2018;21(12):2059-2062.
Bandinelli F, Benucci M, Salaffi F, et al. Do new and old biomarkers of early undifferentiated arthritis correlate with the Arthritis Impact Measurement Scales? Clin Exp Rheumatol. 2021;39(1):79-83.
Abbasi M, Mousavi MJ, Jamalzehi S, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234(7):10018-10031.
Conti V, Corbi G, Costantino M, et al. Biomarkers to personalize the treatment of Rheumatoid arthritis: focus on autoantibodies and pharmacogenetics. Biomolecules. 2020;10(12):1672.
Ali ET, Jabbar AS, Mohammed AN. A comparative study of interleukin 6, inflammatory markers, ferritin, and hematological profile in Rheumatoid arthritis patients with anemia of chronic disease and iron deficiency anemia. Anemia. 2019;2019:3457347.
Kim JH. Interleukin-8 in the tumor immune niche: lessons from comparative oncology. Adv Exp Med Biol. 2020;1240:25-33.
Lockwood CJ, Arcuri F, Toti P, et al. Tumor necrosis factor-alpha and interleukin-1beta regulate interleukin-8 expression in third trimester decidual cells: implications for the genesis of chorioamnionitis. Am J Pathol. 2006;169(4):1294-1302.
Huang Y, Zheng S, Wang R, Tang C, Zhu J, Li J. CCL5 and related genes might be the potential diagnostic biomarkers for the therapeutic strategies of rheumatoid arthritis. Eur J Immunol. 2019;49:885.
Guo X, Wang SL, Godwood A, et al. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis. Int J Rheum Dis. 2019;22(4):646-653.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588.
Al-Ghamdi AA. The co-morbidities and mortality rate among Rheumatoid arthritis patients at the Western Region of Saudi Arabia: a retrospective cross-sectional study. J King Abdulaziz Univ Med Sci. 2009;16(3):15-29.
Fang QH, Ou JX, Nandakumar KS. Autoantibodies as diagnostic markers and mediator of joint inflammation in arthritis. Mediators Inflamm. 2019;2019:1-22.
Mohammed RHA, Goyal A, Bansal P. Hand and Wrist Rheumatoid Arthritis. StatPearls. StatPearls Publishing LLC; 2021 pp. StatPearls Publishing Copyright © 2021.
Son KM, Kang SH, Seo YI, Kim HA. Association of body composition with disease activity and disability in rheumatoid arthritis. Korean J Intern Med. 2021;36(1):214-222.
Alballa SR. The expression of rheumatoid arthritis in Saudi Arabia. Clin Rheumatol. 1995;14(6):641-645.
Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727-734.
Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ. 2012;345:e5244.
Wu CY, Yang HY, Luo SF, Lai JH. From Rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with Rheumatoid arthritis. Int J Mol Sci. 2021;22(2):686.
Pope JE, Choy EH. C-reactive protein and implications in Rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219-229.
England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended Rheumatoid arthritis disease activity measures. Arthrit Care Res. 2019;71(12):1540-1555.
Kaneko Y, Kondo H, Takeuchi T. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol. 2013;40(1258):1254-1258.
Ali A, Abbasi AS, Amjad T, Saleem F. Erythrocyte sedimentation rate and C-reactive protein as marker of acute versus chronic medical conditions. J Ayub Med Coll Abbottabad. 2019;31(1):39-45.
Zhang J, Bai C. Elevated serum interleukin-8 level as a preferable biomarker for identifying uncontrolled asthma and glucocorticosteroid responsiveness. Tanaffos. 2017;16(4):260-269.
Morita T, Shima Y, Fujimoto K, et al. Anti-receptor activator of nuclear factor kappaB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis. Int Immunol. 2019;31(5):277-285.
Shrivastava AK, Pandey A. Inflammation and rheumatoid arthritis. J Physiol Biochem. 2013;69(2):335-347.
Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther. 2000;6(2):71-79.
Lo SF, Huang CM, Lin HC, Chen WC, Tsai CH, Tsai FJ. Cytokine (IL-6) and chemokine (IL-8) gene polymorphisms among rheumatoid arthritis patients in Taiwan. Clin Exp Rheumatol. 2008;26(4):632-637.
Onodera S, Nishihira J, Koyama Y, et al. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta. Arthritis Rheum. 2004;50(5):1437-1447.
Nicolau J, Lequerre T, Bacquet H, Vittecoq O. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017;84(4):411-416.
Chalan P, Bijzet J, van den Berg A, et al. Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients. Sci Rep. 2016;6:26021.
Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988;2(8613):706-709.
Verbruggen A, De Clerck LS, Bridts CH, Van Offel JF, Stevens WJ. Flow cytometrical determination of interleukin 1beta, interleukin 6 and tumour necrosis factor alpha in monocytes of rheumatoid arthritis patients; relation with parameters of osteoporosis. Cytokine. 1999;11(11):869-874.
Salvarani C, Casali B, Salvo D, et al. The role of interleukin 1, erythropoietin and red cell bound immunoglobulins in the anaemia of rheumatoid arthritis. Clin Exp Rheumatol. 1991;9(3):241-246.
Tournadre A, Pereira B, Dutheil F, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-646.
Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021;80(1):96-102.
Zhang C. Flare-up of cytokines in rheumatoid arthritis and their role in triggering depression: Shared common function and their possible applications in treatment (Review). Biomed Rep. 2021;14(1):16.
Boyapati A, Schwartzman S, Msihid J, et al. Association of high serum interleukin-6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis. Arthritis Rheumatol. 2020;72(9):1456-1466.
Shi R, Chen M, Litifu B. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol. 2018;28(1):126-132.
Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885-1895.
Li YC, Chou YC, Chen HC, Lu CC, Chang DM. Interleukin-6 and interleukin-17 are related to depression in patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22(6):980-985.
Yip RML, Yim CW. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. J Clin Rheumatol. 2021;27(8):e516-e524.
White KK, Jester A, Bache CE, et al. Orthopedic management of the extremities in patients with Morquio A syndrome. J Child Orthop. 2014;8(4):295-304.
Ellingsen T, Hansen I, Thorsen J, et al. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression. Scand J Rheumatol. 2014;43(2):91-100.
Sellam J, Rouanet S, Hendel-Chavez H, et al. CCL19, a B cell chemokine, is related to the Decrease of blood memory B cells and predicts the clinical response to rituximab in patients with Rheumatoid arthritis. Arthritis Rheum-Us. 2013;65(9):2253-2261.
Sucur A, Jajic Z, Artukovic M, et al. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells. Arthritis Res Ther. 2017;19(1):142.
Bahlas S, Damiati L, Dandachi N, Sait H, Alsefri M, Pushparaj PN. Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using Luminex Multiple Analyte Profiling technology for precision medicine. Clin Exp Rheumatol. 2019;37(1):112-119.
Elemam NM, Hannawi S, Maghazachi AA. Role of chemokines and chemokine receptors in Rheumatoid arthritis. Immunotargets Ther. 2020;9:43-56.
Yang MH, Wu FX, Xie CM, et al. Expression of CC chemokine ligand 5 in patients with rheumatoid arthritis and its correlation with disease activity and medication. Chin Med Sci J. 2009;24(1):50-54.
Portales P, Fabre S, Vincent T, et al. Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody. Immunology. 2009;128(1 Suppl):e738-e745.
Huang YE, Zheng SY, Wang R, Tang CP, Zhu JQ, Li J. CCL5 and related genes might be the potential diagnostic biomarkers for the therapeutic strategies of rheumatoid arthritis. Clin Rheumatol. 2019;38(9):2629-2635.
Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49-62.
Tikhonova IA, Yang H, Bello S, et al. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2021;25(8):1-248.
Thilagar S, Theyagarajan R, Sudhakar U, Suresh S, Saketharaman P, Ahamed N. Comparison of serum tumor necrosis factor-alpha levels in rheumatoid arthritis individuals with and without chronic periodontitis: a biochemical study. J Indian Soc Periodontol. 2018;22(2):116-121.
Fiocco U, Sfriso P, Oliviero F, et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine. 2013;80(2):165-170.